Co-Diagnostics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Salt lake city , july 27, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) ("co-dx" or the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be attending and speaking at the yale school of public health salivadirect™ conference held july 28-29 in chicago, il. the mission of yale's salivadirect is to advance the use of saliva-based testing as a readily-deployable, sensitive, patient-friendly option that increases access to affordable and equitable infectious disease testing.

The company will also be providing an update to its distributors and other customers on july 26 at 11 am ct. salt lake city , july 20, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth to showcase its existing and upcoming suite of diagnostics products and technology applications at the 2022 aacc annual scientific meeting & clinical lab expo, held july 24-28 at the mccormick place convention center in chicago, il, in addition to providing an update for its worldwide network of customers and distributors.

Salt lake city , july 11, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq-cm: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has shipped testing reagents for monkeypox virus currently exhibiting a multi-country outbreak to one of its international distributors. according to the world health organization (who), monkeypox is a virus originally transmitted to humans from animals, and then transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding.

Wilmington, delaware--(newsfile corp. - june 27, 2022) - rigrodsky law, p.a. is investigating potential claims against the officers and directors of co-diagnostics, inc. (nasdaqcm: codx) on behalf of stockholders.to learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-co-diagnostics-inc.to contact seth d. rigrodsky or gina m. serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.rigrodsky law, p.a., with offices in delaware and new york, has recovered hundreds of millions of dollars on behalf...

Salt lake city , june 9, 2022 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 22nd medexpo africa 2022, held june 9-11 in nairobi, kenya. the largest international medical trade exhibition in the country features exhibitors from over 30 countries, all profiling innovative solutions from leaders in the medical technology industry, and targeted toward buyers from across the continent seeking new products, equipment, machinery, services and solutions.

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Co-Diagnostics Inc (NASDAQ:CODX) (Co-Dx) has announced that it will be disclosing the global expansion of its original equipment manufacturer (OEM) agreement with Bio Molecular Systems (BMS) at the company's customer and distributor update today at the American Association for Clinical Chemistry's (AACC) Annual Scientific Meeting & Clinical Lab Expo. The molecular diagnostics firm said the expanded branding and distribution OEM agreement increases Co-Diagnostics' approved sales territories to 193 countries worldwide.

SALT LAKE CITY , July 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing the original Rotor-Gene Real-Time PCR instrument, with a reputation for expertise in developing innovative, versatile, robust, and easy-to-use products.

CODX stock is up during early afternoon trading as Co-Diagnostics ships out monkeypox testing reagents to help deal with the outbreak. The post CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests appeared first on InvestorPlace.

The medical test maker just got its new test for monkeypox out the door for the first time.

Co-Diagnostics (NASDAQ:CODX) Inc announced it has shipped testing reagents for the monkeypox virus, currently exhibiting a multi-country outbreak, to one of its international distributors. In a statement, the molecular diagnostics company said the products shipped were designed and developed on an expedited basis to meet the demands in the distributor's region.

Investors in the diagnostics and research outfit received a dose of beneficial news today.

SALT LAKE CITY , June 28, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th International Biodetection Technologies Conference, held virtually June 28-29, 2022. The Biodetection Technologies Conference is an internationally recognized meeting for experts in detection & identification of biological threats, which this year plans to address the key topics in detection and present the latest R&D and technological innovation in ready-to-market systems.

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

SALT LAKE CITY , June 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Summer Small Cap Virtual Investor Conference June 15-16, 2022. The presentation will begin at 3:15 p.m.